Augmem™ Science


Augmem™ uses neural circuit-based approaches backed by proprietary AI to create highly sensitive digital cognitive assessment tools.

The underlying science is informed by over 15 years of research more than 50 peer-reviewed publications.

Augmem™ is based on several decades of computational and empirical research across species that has now reliably demonstrated that memory for everyday events requires a process known as “pattern separation”.

This process allows our brains to create unique memories for similar experiences (for example, where you parked your car today vs. yesterday) and enabling us to store and retain rich, detailed memories of our past.

As we all get older, we begin to struggle with pattern separation, leading to a loss of contextual memories (where certain events occurred or when they occurred). Most of these changes can be benign and part of the normal aging process. Individuals affected by Alzheimer’s disease struggle to a much greater extent.

Work by Dr. Yassa and colleagues has shown that loss of pattern separation can be an early marker of memory loss in Alzheimer’s disease, prior to the onset of clinical symptoms.

Augmem™ is a digital cognitive assessment platform targeting pattern separation, coupled with an artificial intelligence (AI) engine that generates unprecedented insights into the cognitive processes and brain systems that underlie memory loss. It is highly sensitive to even the most subtle shifts in cognition and has been extensively validated using brain imaging studies.

Selected Publications

Marco Peters, Ph.D.

Co-Founder and Scientific Advisor

Dr. Peters has over 20 years of experience in translational research, target discovery, and small molecule discovery for CNS indications. He built and managed small and large research teams, and his work has contributed to the discovery, progression, and clinical development of small molecule therapeutics for the treatment of multiple neurological indications including stroke, Alzheimer’s Disease, Parkinson’s disease, pain, and schizophrenia. He currently serves as vice president and head of translational science at Longboard Pharmaceuticals. Peters built the departments of Neurobiology and Behavioral Pharmacology, and managed target identification, in vivo pharmacology, and lead optimization at Dart Neuroscience. His work contributed to the advancement of multiple compounds into clinical development, and led to a broad intellectual property portfolio focused on enhancement of brain plasticity and cognitive function. Peters has a M.Sc. in Biochemistry from the Freie Universität Berlin, Germany and a PhD in Neuroscience from the University of London, UK. He conducted postdoctoral work on Alzheimer’s disease with Tetsuyuki Maruyama at Merck Sharp & Dohme (UK).